Since tamoxifen is commonly used for the treatment of ERα+/HER2- breast cancer, we thus investigated whether loss of Frmd8 affects sensitivity of mammary tumors to tamoxifen treatment in mice. Here, ESR1 is linked to breast carcinoma.